Premium
Combined use of orgaran and reopro during coronary angioplasty in patients unable to receive heparin
Author(s) -
Cantor Warren J.,
Leblanc Kori,
Garvey Bernadette,
Watson K. Randal,
Rasymas Al,
Strauss Bradley H.
Publication year - 1999
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/(sici)1522-726x(199903)46:3<352::aid-ccd21>3.0.co;2-7
Subject(s) - medicine , angioplasty , heparin , heparinoid , abciximab , cardiology , intravenous bolus , bolus (digestion) , percutaneous coronary intervention , myocardial infarction
Orgaran, a heparinoid, has been used successfully in patients with heparin‐induced thrombocytopenia. We report three cases in which Orgaran was combined with the glycoprotein IIb/IIa receptor antagonist Reopro during coronary angioplasty. Orgaran was given as a single intravenous bolus of 1500 anti‐factor Xa units. No ischemic or hemorrhagic complications occurred during or following the procedure. Cathet. Cardiovasc. Intervent. 46:352–355, 1999. © 1999 Wiley‐Liss, Inc.